Larimar Therapeutics, Inc.
LRMRHeld by 6 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying6 funds opened new positions. Next phase2 readout (CTI-1601): Jan 2027. Short interest: 22.9% of float.
Held by 6 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying6 funds opened new positions. Next phase2 readout (CTI-1601): Jan 2027. Short interest: 22.9% of float.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.